J&J has submitted 2 supplemental BLAs applying for FDA approval of guselkumab( Tremfya) for use in juvenile plaque psoriasis & juvenile (>5-6 yrs age) psoriatic arthritis based on several phase 3 RCTs. https://t.co/dAkH219pzN https://t.co/R9yJCSOVJa
Links:
Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for T…
https://buff.ly/3ZmVu26
Dec-03-2024
